Advancing Duchenne Muscular Dystrophy Treatments Through Protein Interactions
New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective therapeutic approaches.
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu
Capricor Completes Submission Of BLA For Deramiocel For Treatment Of Duchenne Muscular Dystrophy
"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially transformational therapy to those patients in need,
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology firm specializing in innovative cell and exosome-based therapies for rare diseases, finalized the submission of its Biologics License Application (BLA) to the U.
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.
Capricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s Excited
Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it completed the submission of its Biologics License Application (BLA) for for Deramiocel to the U.
Pharmaceutical Technology15h
Delpacibart zotadirsen by Avidity Biosciences for Duchenne Muscular Dystrophy: Likelihood of Approval
Delpacibart zotadirsen is under clinical development by Avidity Biosciences and currently in Phase II for Duchenne Muscular Dystrophy.
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...
Managed Healthcare Executive2d
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
New insights into protein roles in Duchenne muscular dystrophy
A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and ...
Armed robbery in Revesby5d
Research Reveals Protein Insights for Duchenne Therapy
Study results provide root explanations for how dystrophin functions on a molecular level, providing base-level insights into ...
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential ...
Science Daily6d
New study uncovers key insights into protein interactions in Duchenne muscular dystrophy, paving way for more targeted therapies
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...